Apex Medical Technologies (United States)

BackgroundThere are some motion platforms for radiotherapy quality assurance. However, no platform with two drive systems that can move along three axes is available.PurposeThe purpose of this study is to develop a dynamic motion platform with two drive systems capable of three‐axis motion and to evaluate its motion performance.MethodsThe developed moving platform had two drive systems that use the same equipment. Each axis of the platform used can support a maximum load of 10 kg. The motors for moving the platform in each direction are capable of a drive stroke up to 40 mm. The drive speed is 30 mm/s at maximum load fluctuation. To evaluate the static positional accuracy of this system with an arbitrary input movement, the XYZ position of each axis was measured using a coordinate measuring machine operating from 0 to 40 mm at 10 mm intervals. In addition, the accuracy of dynamic motion was verified with Sine waveform inputs of different patterns to the three axes for approximately 60 s, and they were compared with the resulting detected signals by SyncTrax.ResultsThe two drive systems were successfully operated on three axes by using independent control systems. For static position, the accuracies were within 0.2 mm, 0.05 mm, and 0.14 mm for lateral, longitudinal, and vertical directions, respectively. For dynamic motion, the mean absolute errors in the X, Y, and Z axes between the platform inputs and SyncTrax detected signals were 0.14 ± 0.10 mm, 0.16 ± 0.12 mm, and 0.16 ± 0.11 mm, respectively.ConclusionsA new dynamic platform for radiation therapy with two drive systems capable of three‐axis motion was developed, and the positional accuracy of the drive axes was confirmed to be less than 0.2 mm.

Bei T2D-Patienten mit unzureichender glykämischer Kontrolle unter Metformin (Ausgangs-HbA1c 8 – 12%) senkte eine Zweifachtherapie mit Depot-Exenatide+Dapagliflozin (DAPA) über 28 Wochen den Blutglukosespiegel, das Gewicht und den systolischen Blutdruck (SBD) signifikant stärker als Depot-Exenatide+Placebo oder DAPA+Placebo, wobei keine unerwarteten Sicherheitssignale auftraten (DURATION-8-Studie: NCT02229396).

We assessed the clinical features and outcomes based on therapeutic options adopted during hospital stay for adult patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis (MAS/sHLH). We conducted a retrospective chart review of all adult patients (age ≥18years) diagnosed with MAS/sHLH at our center between 2010 and 2015. Inclusion criteria for patients were diagnosis of MAS/sHLH during admission and patients meeting at least 5 out of 8 of Henter's criteria or at least 4 out of 6 of the criteria that were tested. Nineteen adult patients with MAS/sHLH met the inclusion criteria from January 2010 to October 2015 (median age 48years; female 68.4%). Treatment had been personalized, depending on the clinical presentation and course of disease. Majority of the patients received anakinra, cyclosporine, intravenous immunoglobulins (IVIG), and steroids. Fourteen (74%) patients survived, with clinical improvement by the time of discharge. After excluding the three patients with underlying leukemia/lymphoma who opted for palliative care and subsequently died, the survival rate was 88%. A modified diagnostic and treatment protocol for adult patients with MAS/sHLH that incorporated graded introduction of medications based on clinical presentation and cytokine profile resulted in the best adult survival rate reported in literature.